To deepen collaboration between Shenzhen and Hong Kong in stem cell technology and drive advancements in cutting-edge medical solutions, the "Shenzhen-Hong Kong Stem Cell Technology Industry Exchange Event" was held at Starlight Hotel in Hong Kong's Tsim Sha Tsui on April 22,2025. Co-organized by Shenzhen Municipal Bureau of Pharmaceutical and Medical Device Industry and Qianhai Administrative Bureau, the event brought together government officials, leaders from Shenzhen's top enterprises, representatives from Hong Kong industry associations, and university experts to explore new opportunities in stem cell research. Professor Shi Yuanyuan, Chairman of our company, delivered a keynote speech sharing scientific achievements, innovative practices, and future prospects in the cell and gene therapy sector.

At the conference, Professor Shi Yuanyuan elaborated on Shenzhen Cell Valley's core technologies, products and services, research achievements, clinical progress, as well as the technological advantages of stem cells, NK cells, and exosomes. Leveraging its independently developed SDAP full-process industrialization technology, Shenzhen Cell Valley has achieved breakthroughs in cell therapy by successfully overcoming the challenge of large-scale production of allogeneic NK cells, significantly improving production efficiency. Additionally, the company implements GMP-compliant quality control throughout exosome production processes. Its self-developed "Umbilical Cord Mesenchymal Stem Cell Vesicles" (INCI code: 38292, INCI name: Umbilical Mesenchymal Stem Cell Vesicles, commercial name: CVEXSOTM) has been officially approved by the International Cosmetic Ingredient Naming Committee (INC) and included in the "International Cosmetic Ingredient Dictionary and Manual". Professor Shi emphasized that Shenzhen Cell Valley has systematically addressed three major pain points in cell therapy—difficult mass production, high costs, and weak quality control—through a three-dimensional approach combining technological innovation, process upgrades, and full-chain quality control. The company has now established a complete industrial closed-loop from R&D to clinical translation, laying a solid foundation for the development of cell and gene therapy industries.